India takes action on spurious and sub-standard drugs

10 November 2014
drugs_pills_tablets_big

An American pharmacist and an Indian pharmacologist charged with smuggling four million fake pharmaceuticals into the country earlier this month may have been the last straw for the Indian government battling counterfeit drugs.

Summons have been issued to carry out an all-India survey on the availability and the extent of spurious and sub-standard drugs in the country, while law enforcement agencies have been ordered to aggressively pursue counterfeiters and put them behind bars, reports The Pharma Letter’s India correspondent.

Fake drugs, that treat everything from cancer to erectile dysfunction, are a multibillion dollar industry. With many accusing fingers pointing to India, the country has decided to don battle gear against sub-standard pharmaceutical products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics